Protalix BioTherapeutics (PLX) Research & Development (2010 - 2026)

Protalix BioTherapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $5.4 million for Q1 2026.

• In Q1 2026, Research & Development rose 56.14% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $21.5 million (up 58.73% YoY), while the FY2025 annual figure was $19.6 million, up 50.88% from the prior year.
• Research & Development was $5.4 million for Q1 2026 at Protalix BioTherapeutics, down from $5.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $8.8 million in Q1 2022 to a low of $2.9 million in Q1 2024.
• Historically, Research & Development has averaged $5.0 million across 5 years, with a median of $4.5 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Research & Development plunged 50.62% in 2024, then surged 102.36% in 2025.
• A 5-year view of Research & Development shows it stood at $5.6 million in 2022, then tumbled by 44.77% to $3.1 million in 2023, then surged by 32.95% to $4.1 million in 2024, then jumped by 36.64% to $5.6 million in 2025, then dropped by 3.71% to $5.4 million in 2026.
• The last three Research & Development figures came in at $5.4 million (Q1 2026), $5.6 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.